A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

@inproceedings{Smolen2017ARD,
  title={A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis},
  author={Josef S Smolen and Stanley B. Cohen and H. -P. Tony and Morton Aaron Scheinberg and Alan J. Kivitz and Andra Rodica Bălănescu and Juan Luiz Gomez-Reino and Liyi Cen and Peijuan Zhu and Tam{\'a}s Shisha},
  booktitle={Annals of the rheumatic diseases},
  year={2017}
}
OBJECTIVES The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar efficacy, safety and immunogenicity between GP2013, a biosimilar rituximab, and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitor (TNFi) treatment. METHODS In this multinational, randomised, double-blind, parallel-group study, 312 patients with active disease despite prior… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 11 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

GP2013: A Rituximab Biosimilar

BioDrugs • 2017
View 10 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…